Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17393082 | 1.00 | ALDH1A1 (0.38) | ALDH1A1GAAPOLBL3MBTL1MEN1 | |
| SCHEMBL19115674 | 0.86 | MAPT (0.31) | ALDH1A1GAAPOLBMAPT | |
| SCHEMBL19251669 | 0.85 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL16284394 | 0.82 | ALDH1A1 (0.35) | ALDH1A1GAAPOLBL3MBTL1MEN1 | |
| SCHEMBL13813386 | 0.81 | ALDH1A1 (0.38) | ALDH1A1GAAPOLBL3MBTL1MEN1 | |
| SCHEMBL21121000 | 0.81 | HRH3 (0.38) | ALDH1A1POLBTSHR | |
| SCHEMBL21291301 | 0.80 | L3MBTL3 (0.39) | ALDH1A1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL12091668 | 0.80 | TSHR (0.38) | ALDH1A1GAAPOLBMEN1KMT2A | |
| SCHEMBL5839782 | 0.78 | ALDH1A1 (0.37) | ALDH1A1GAAPOLBL3MBTL1MEN1 | |
| SCHEMBL16975487 | 0.78 | ALDH1A1 (0.41) | ALDH1A1GAAPOLBL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11530229-B2 | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof | NURIX THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11219625-B2 | Inhibitors of N-linked glycosylation and methods using same | YALE UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| US-7985764-B2 | Amide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20110070168-A1 | MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7411004-B2 | Alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2008-08-12 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070168-A1 | MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, ZC3HAV1, ZC3HAV1L | ALDH1A1 4490/4885GAA 2746/4885POLB 743/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | ALDH1A1 3439/4885GAA 164/4885POLB 692/4885 |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | ALDH1A1 1722/4885GAA 1747/4885POLB 413/4885 |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | ALDH1A1 3197/4885GAA 1925/4885POLB 2853/4885 |
| US-11530229-B2 | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof | CBLB, CBL, CBLC | ALDH1A1 4692/4885GAA 1063/4885POLB 265/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | ALDH1A1 1535/4885GAA 234/4885POLB 2852/4885 |
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | HTR7, HTR2B, NPSR1 | ALDH1A1 3607/4885GAA 4756/4885POLB 4244/4885 |
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | P2RX4, P2RX3, P2RX2 | ALDH1A1 1462/4885GAA 3503/4885POLB 4416/4885 |
| US-11219625-B2 | Inhibitors of N-linked glycosylation and methods using same | ENGASE, FUT5, B3GNT2 | ALDH1A1 2118/4885GAA 13/4885POLB 2967/4885 |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | ALDH1A1 1210/4885GAA 4234/4885POLB 4665/4885 |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | ALDH1A1 4322/4885GAA 845/4885POLB 2567/4885 |
| US-11578087-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | ALDH1A1 585/4885GAA 125/4885POLB 560/4885 |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | PCK1, PDK2, PDK1 | ALDH1A1 1403/4885GAA 546/4885POLB 1325/4885 |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | CBLB, CBL, CBLC | ALDH1A1 4692/4885GAA 1063/4885POLB 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.